With over 20 years of healthcare investor relations experience combined with prior banking roles, Stephanie provides strategic communications counsel to emerging biotechnology and specialty pharmaceutical companies, both pre- and post-IPO. She combines deep knowledge of the life sciences & diagnostics sectors and the investment community to serve as a trusted IR partner for C-suite executives.

Stephanie invests the resources to be well versed in each healthcare client’s corporate strategy and competitive position in order to develop customized programs to raise visibility for their differentiated science, lead candidates, clinical development pathway and commercialization strategy. She is well versed in partnering with privately companies to raise their profiles across targeted VC and crossover audiences, and navigate the transition to public ownership. Throughout her career, Stephanie has represented biotechnology and specialty pharmaceutical companies from a wide range therapeutic areas spanning such areas as oncology, central nervous system, respiratory, infectious disease, dermatology, pain management, ophthalmology, and cardiology.

Prior to joining Westwicke , an ICR Company, Stephanie held position in the investor relations field with increasing levels of responsibility as a Senior Vice President of Investor Relations at The Ruth Group, an Assistant Vice President Morgen-Walke Associates, and a Senior Associate at The Financial Relations Board. Earlier, Stephanie held positions at Alliance Capital Management, Bankers Trust and the Federal Reserve Bank of New York. She earned a BA in Economics and International Relations from Smith College and an MBA in Finance and International Business from New York University’s Stern School of Business.